ANIK - NASDAQ

Anika Therapeutics, Inc.

ANIK·NASDAQ

$14.41

+0.49%

HealthcareMedical - Devices

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$191.73M

EPS-0.7600

P/E Ratio-18.96

Earnings Date07/29/2026

190.27M

Assets

-6%

3Y-46.0%

5Y-48.0%

10Y-21.0%

46.80M

Total Liabilities

-4%

3Y-26.0%

5Y-50.0%

10Y+168.0%

143.47M

Total Equity

-7%

3Y-50.0%

5Y-47.0%

10Y-36.0%

Anika Therapeutics, Inc. Funding & Solvency Profile

ANIK · NASDAQ

Current Assets

Cash & Cash Equivalents57.48M

Net Receivables23.69M

Inventory18.79M

Other Current Assets3.40M

Total Current Assets103 M

Non-Current Assets

Property, Plant & Equipment66.26M

Goodwill & Intangible Assets9.70M

Long-Term Investments0.00

Other Non-Current Assets9.67M

Total Non-Current Assets76 M

Total Assets

190.27M

Financial Health Analysis

Current Ratio

4.72x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.33x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

81 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

54% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Anika Therapeutics, Inc. Balance Sheet

ANIK • NASDAQ

Anika Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	57.5M	55.6M	68.7M	86.3M	94.4M	95.8M	157.5M	89M	133.3M	104.3M	110.7M	100.2M	63.3M	44.1M	35.8M	28.2M	24.4M	43.2M	35.9M	47.2M
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	2.5M	27.5M	70M	24M	20.5M	27.8M	6.8M	0.0	0.0	0.0	0.0	0.0	0.0	3.5M	0.0
Cash & Short-Term Investments	57.5M	55.6M	68.7M	86.3M	94.4M	98.3M	184.9M	159M	157.3M	124.8M	138.5M	106.9M	63.3M	44.1M	35.8M	28.2M	24.4M	43.2M	39.4M	47.2M
Net Receivables	23.7M	23.6M	26.4M	34.6M	29.8M	24.1M	23.1M	20.8M	23.8M	27.6M	21.7M	17.2M	18.7M	21.5M	17.3M	14.8M	11.8M	5.4M	5.8M	3.5M
Accounts Receivables	23.7M	23.6M	26.4M	34.6M	29.8M	24.1M	23.1M	20.8M	23.8M	27.6M	21.7M	17.2M	18.7M	21.5M	17.3M	14.8M	11.8M	5.4M	5.8M	3.5M
Inventory	18.8M	23.8M	24.4M	39.8M	36M	46.2M	22M	21.3M	22M	16M	14.9M	12.4M	11M	8.3M	7.3M	8.9M	8.4M	5.5M	4.4M	5.4M
Prepaids	0.0	0.0	0.0	8.8M	8.3M	8.8M	4.3M	1.9M	3.2M	2.1M	1.4M	1.4M	866K	1.5M	1.8M	2.4M	2.9M	463.3K	1.2M	220.4K
Other Current Assets	3.4M	10.6M	43.8M	0.0	0.0	0.0	1.4M	0.0	0.0	0.0	0.0	0.0	659K	3.6M	1.9M	2M	2.2M	1.2M	1.7M	1.3M
Total Current Assets	103.4M	113.7M	163.3M	169.5M	168.5M	177.4M	235.7M	202.9M	206.3M	170.4M	176.4M	139M	94.6M	77.4M	64.1M	56.3M	49.8M	55.8M	52.4M	57.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	66.3M	64.7M	65M	79M	68.6M	73.2M	73.6M	54.1M	56.2M	52.3M	40.1M	31.7M	32.9M	35.1M	36.5M	37M	35.7M	32.2M	19.4M	3M
Goodwill	8.1M	7.1M	7.6M	7.3M	7.8M	8.4M	7.7M	7.9M	8.2M	7.2M	7.5M	8.3M	9.4M	9.1M	8.9M	9.1M	7.7M	0.0	0.0	0.0
Intangible Assets	1.7M	2.5M	2.6M	74.6M	82.4M	91.2M	7.6M	9.2M	10.6M	10.2M	11.7M	14.9M	19M	20.3M	23.1M	25.8M	33.6M	936.3K	995.1K	0.0
Goodwill & Intangible Assets	9.7M	9.6M	10.1M	81.9M	90.2M	99.6M	15.3M	17M	18.9M	17.4M	19.1M	23.2M	28.4M	29.4M	32M	34.9M	41.2M	936.3K	995.1K	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	-11.5M	-7.2M	-4.8M	0.0	0.0	-1.2B	-659M	-2B	-1.9B	0.0	0.0	506.8K	0.0	0.0
Tax Assets	1.3M	1.2M	1.5M	1.4M	0.0	0.0	11.5M	7.2M	4.8M	0.0	0.0	1.2B	659M	2B	1.9B	392K	3.5M	6.3M	6.3M	7.3M
Other Non-Current Assets	9.7M	13.6M	30.7M	17.2M	20.3M	15.4M	7.5M	4.9M	1.3M	69K	69K	69K	69.1K	171.1K	205K	385K	413.2K	0.0	433.1K	193.1K
Total Non-Current Assets	86.9M	89.1M	107.3M	179.6M	179M	188.2M	96.4M	76.1M	76.3M	69.8M	59.3M	55M	61.5M	64.7M	68.7M	72.6M	80.9M	40M	27.1M	10.5M
Other Assets	0.0	0.0	0.0	0.0	0.0	0.0	-1.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	190.3M	202.7M	270.6M	349.1M	347.5M	365.6M	330.7M	279M	282.6M	240.2M	235.7M	194M	156M	142.1M	132.8M	128.9M	130.7M	95.8M	79.5M	68.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	6M	5.7M	7.4M	9.9M	7.6M	9M	3.8M	3.1M	6.7M	2.3M	8.3M	1.2M	3.6M	4.1M	4.8M	9.7M	6.4M	2.4M	5.1M	965.2K
Accounts Payable	6M	5.6M	6.2M	9.1M	7.6M	9M	3.8M	3.1M	6.7M	2.3M	8.3M	1.2M	2.8M	2.3M	4.3M	9.7M	6.4M	2.4M	4.9M	965.2K
Other Payables	0.0	63K	1.2M	810K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	452.0	770.3K	1.8M	450.5K	0.0	24.4K	0.0	204K	0.0
Accrued Expenses	0.0	3.5M	3.1M	4.7M	6.6M	5.9M	11.3M	4.4M	2.9M	3.1M	3.1M	2.8M	2.7M	5.8M	5.3M	5.4M	5.8M	2.3M	2.8M	1.6M
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6M	1.6M	1.6M	1.6M	1.6M	0.0	0.0
Capital Lease Obligations (Current)	0.0	1.9M	1.8M	2.1M	1.7M	1.6M	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	63K	1.2M	810K	0.0	0.0	0.0	385K	0.0	0.0	4.2M	412.3M	770.3K	1.8M	450.5K	0.0	0.0	0.0	204M	17.3M
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	48K	66K	24.5K	180.4K	2.9M	2.9M	2.7M	2.8M	2.7M	2.8M	2.9M
Other Current Liabilities	15.9M	12.2M	18.7M	11.3M	13.8M	20.4M	0.0	3.7M	3.4M	3.4M	5.9M	2M	2.8M	0.0	0.0	0.0	0.0	0.0	0.0	17.3K
Total Current Liabilities	21.9M	23.3M	31.1M	27.9M	29.8M	36.9M	16.3M	11.3M	13.1M	8.8M	17.3M	6M	9.3M	14.5M	14.5M	19.4M	16.5M	9M	10.6M	5.5M
NON-CURRENT LIABILITIES
Long Term Debt	24.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8M	9.6M	11.2M	12.8M	14.4M	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	48K	66K	102.2K	2.1M	2.2M	5M	5.4M	8.1M	10.8M	13.5B	17.1B
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	6.4M	10.2M	11.9M	4.3M	3.5M	5.4M	6.5M	6.8M	8.9M	7.9M	7M	7.4M	6.2M	9.3M	-14.4B	0.0	0.0
Other Non-Current Liabilities	701K	1.4M	1.4M	398K	1.3M	23.6M	357K	550K	660K	2.1M	781K	893.9K	1.1M	1.5M	1.5M	1.6M	1.8M	831.1K	398.4K	64.5K
Total Non-Current Liabilities	24.9M	25.4M	27.3M	35.7M	30.7M	56.3M	26.1M	4.1M	6.1M	8.7M	7.6M	9.9M	11.1M	18.7M	23.5M	24.4M	32M	26M	13.9M	17.2M
Capital Lease Obligations	0.0	25.9M	27.7M	30.9M	21M	22.5M	21.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	46.8M	48.8M	58.4M	63.6M	60.5M	93.2M	42.3M	15.4M	19.1M	17.5M	24.9M	15.9M	20.4M	33.1M	38.1M	43.7M	48.6M	35.1M	24.5M	22.6M
SHAREHOLDERS' EQUITY
Common Stock	139K	144K	147K	146K	144K	143K	143K	142K	147K	146K	150K	148.5K	142.9K	138.7K	136.3K	134.8K	134.2K	113.8K	112.2K	107.7K
Additional Paid-In Capital	0.0	89M	90M	81.1M	67.1M	55.4M	48.7M	50.8M	68.6M	61.7M	81.7M	77.5M	70.6M	65.4M	63.4M	61.8M	60.5M	42.9M	40.7M	37.3M
Retained Earnings	60.8M	71.7M	128.1M	210.7M	225.6M	221.4M	245.4M	218.2M	199.5M	168.2M	135.7M	104.9M	66.6M	46M	34.3M	25.8M	21.5M	17.8M	14.2M	8.1M
Accumulated Other Comprehensive Income/Loss	-5M	-6.8M	-5.9M	-6.4M	-5.7M	-4.5M	-5.9M	-5.5M	-4.8M	-7.3M	-6.6M	-4.5M	-1.7M	-2.7M	-3.1M	-2.5M	-11.4M	-10.2M	-8.7M	-10.2M
Other Total Stockholders' Equity	87.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-301.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	143.5M	154M	212.3M	285.6M	287.1M	272.4M	288.4M	263.6M	263.5M	222.8M	210.8M	178.1M	135.6M	108.9M	94.8M	85.2M	82.1M	60.8M	55M	45.5M
Total Equity	143.5M	154M	212.3M	285.6M	287.1M	272.4M	288.4M	263.6M	263.5M	222.8M	210.8M	178.1M	135.6M	108.9M	94.8M	85.2M	82.1M	60.8M	55M	45.5M
SUMMARY
Total Liabilities & Equity	190.3M	202.7M	270.6M	349.1M	347.5M	365.6M	330.7M	279M	282.6M	240.2M	235.7M	194M	156M	142.1M	132.8M	128.9M	130.7M	95.8M	79.5M	68.1M
Total Investments	0.0	0.0	0.0	0.0	0.0	2.5M	27.5M	70M	24M	20.5M	27.8M	6.8M	-659M	-2B	-1.9B	0.0	0.0	506.8K	3.5M	0.0
Total Debt	24.2M	25.9M	27.7M	30.9M	21M	22.5M	21.4M	0.0	0.0	0.0	0.0	0.0	0.0	9.6M	11.2M	12.8M	14.4M	1.6M	0.0	0.0
Net Debt	-33.3M	-29.7M	-41M	-55.4M	-73.4M	-73.4M	-136.1M	-89M	-133.3M	-104.3M	-110.7M	-100.2M	-63.3M	-34.5M	-24.6M	-15.4M	-10M	-41.6M	-35.9M	-47.2M
Shares Outstanding	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100	14,418,100

SEC Filings

ANIK - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	April 30, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 24, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 18, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 03, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 07, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 05, 2025	November 05, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	July 30, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	July 30, 2025	July 30, 2025	2025	View Filing

Showing 1 to 10 of 371 filings

Related Guides

Blog Categories

Continue your ANIK research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.